department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Diacomit · pharmadog

pharmadog
drugs
Diacomit

drug

patient view →

stiripentol

Marketedupdated 2mo ago

by Biocodex

Approved

community read0 votes

all catalysts(8)

approval · 6

DIACOMIT (STIRIPENTOL) — FDA approval

DIACOMIT (STIRIPENTOL) — FDA approval

DIACOMIT (STIRIPENTOL) — FDA approval

DIACOMIT (STIRIPENTOL) — FDA approval

DIACOMIT (STIRIPENTOL) — FDA approval

DIACOMIT (STIRIPENTOL) — FDA approval

phase 1 completion · 2

phase 1 completion

Life Science OHFC — stiripentol (Phase I Trial Completion)

phase 1 completion

Sun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)

view all 8 catalysts →

News(0)

no news has mentioned this drug yet

brand

Diacomit

generic

stiripentol

indication

Dravet Syndrome (Severe Myoclonic Epilepsy of Infancy)

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Jul 14, 2029

~3.0 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

FDA exclusivities (4)

Jul 14, 2029ODE-403Orphan Drug (7y)3.0y
Jul 14, 2029ODE-403Orphan Drug (7y)3.0y
Jul 14, 2029ODE-403Orphan Drug (7y)3.0y
Jul 14, 2029ODE-403Orphan Drug (7y)3.0y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 52m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 8

drugDIACOMIT26 co-mentions · 8 sources
tagApproval24 co-mentions · 6 sources
companyBiocodex12 co-mentions · 6 sources
tagSmall Molecule12 co-mentions · 6 sources
tagOncology6 co-mentions · 1 sources
companyLife Science OHFC1 co-mentions · 1 sources
companySun Yat-sen University Hospital Seven1 co-mentions · 1 sources
tagNephrology1 co-mentions · 1 sources

Trials studying stiripentol

phase1Bioavailability of Stiripentol After Single Oral Dose of Capsule vs Suspension in Healthy Subjects (STILIQ)completedn=24
phase1Pharmacokinetic Parameters of Stiripentol in Renal Impaired Patients and Matching Controls With Normal Renal Functioncompletedn=39
phase4Study of Interest of Stiripentol and Carbamazepine in the Treatment of Patients With Pharmacoresistant Focal Epilepsiescompletedn=52
phase3Evaluation of the Efficacy and Safety of Stiripentol in Patients 6 Years and Older With Primary Hyperoxaluria Type 1, 2 or 3not yet recruitingn=42